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Emery(32)	 AVERT	 24/52	 0.6	 Naïve¶	 ABA	 125	QW	 R	 15-20	 119	 0	 116	 L,L,L,L,L,L	
Breedveld(34)	 PREMIER	 52/104	 0.7	 Naïve	 ADA	 40	Q2W	 R	 20**	 268	 0	 274	 L,L,L,L,L,L	
Burmester(35)	 CONCERTO	 26/26	 0.3	 Naïve	 ADA	 40	Q2W	 R	 20	 98	 2.5	 98	 L,L,L,L,L,L	
Kaeley(33)	 MUSICA	 24/24	 5.3	 Exp.	 ADA	 40	Q2W	 R	 20	 155	 7.5	 154	 L,L,H,H,L,L	
Klareskog(37)	 TEMPO	 24/52	 6.5	 Naïve/Exp.	 ETA	 25	BIW	 R	 20**	 229	 0	 228	 L,L,L,L,L,L	
Kameda(36)	 JESMR	 24/24	 9.3	 Exp.	 ETA	 25	BIW	 R	 8	 77	 0	 74	 L,L,H,H,L,H	
Emery(38)	 GOBEFORE	 24/24	 3.9	 Naïve	 GOL	 100	Q4W	 H	 20**	 159	 0	 159	 L,L,L,L,L,L	
Keystone(39)	 GOFORWARD	 24/24	 6.3	 Exp.	 GOL	 100	Q4W	 H	 15-25	 89	 0	 133	 L,L,L,L,L,L	







4/kg	Q12W	 H	 128	 129	






L,L,L,L,L,L	3	x	5††	 H	 15	 14	
10	x	5††	 H	 14	 15	
Edwards(42)	 	 24/24	 10.5	 Exp.	 RIT	 1000	x	2§§	 R	 ≥10	 40	 0	 40	 L,L,L,L,L,L	






L,L,L,L,L,H	4/kg	Q4W	 L	 49	 54	
8/kg	Q4W	 R	 50	 52	
Dougados(45)	 ACT-RAY	 24/24	 8.3	 Exp.	 TOC	 8/kg	Q4W	 R	 ≥15	 279	 0	 277	 L,L,L,L,L,L	
Burmester(44)	 FUNCTION	 24/52	 0.5	 Naïve	 TOC	 8/kg	Q4W	 R	 20**	 291	 0	 292	 L,L,L,L,L,L	
Kaneko(46)	 SURPRISE	 24/52	 3.7	 Exp.	 TOC	 8/kg	Q4W	 R	 8.6	 118	 0	 115	 L,U,H,H,L,L	
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Table	2:	Study	characteristics	of	included	Janus	kinase	inhibitor	trials	
























ORAL	Strategy	 24/52	 5.8	 Exp.	 TOF	 5	BD	 R	 15-25	 376	 0	 384	 L,L,L,L,L,L	
Fleischmann	
(49)	
RA-BEGIN	 24/24	 0.7	 Naïve¶	 BAR	 4	OD	 R	 20**	 215	 0	 159	 L,L,L,L,L,L	
Exp.	=	experienced;	BD	=	twice	daily;	OD	=	once	daily;	JAK	=	Janus	kinase;	TOF	=	tofacitinib;	BAR	=	baricitinib	MTX	=	methotrexate;	Dose	cat.	=	dose	category	[L=	below	
recommended,	R=recommended	dose,	H=above	recommended].	*:	benefit/harm.	§:	In	all	individual	trials	JAK	inhibitor	and	dose	were	the	same	in	the	intervention	and	
comparator	groups.	†:	Risk	of	Bias:	Random	sequence	generation	(selection	bias),	Allocation	concealment	(selection	bias),	Blinding	of	participants	and	personnel	
(performance	bias),	Blinding	of	outcome	assessment	(detection	bias),	Incomplete	outcome	data,	Selective	reporting	(reporting	bias).	L	=	Low	risk	of	bias.	U	=	unclear	risk	of	
bias.	H	=	high	risk	of	bias.	¶:	up	to	3	weekly	MTX	doses	permitted.	**:	maximum	end	dose	if	titration	regime	was	necessary.		
	 	
